Elranatamab-bcmm (Elrexfio) demonstrated poorer progression-free survival (PFS) but greater response rates vs eclistamab-cqyv (Tecvayli) in patients with relapsed/refractory multiple myeloma according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback